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Abstract
Background: Atopic dermatitis (AD) is a common skin disorder characterized by chronic inflammation, altered skin
barrier function, and inflammatory cell skin infiltration that decreases health-related quality of life (HRQoL). The
study objective was to understand the patient perspective of AD burden and determine suitable patient-reported
outcome (PRO) measures.
Methods: This mixed methods study involved the collection of qualitative and quantitative information from adults
(≥ 18 years old) and adolescents (12 – 17 years old) with clinician-confirmed AD regarding their experiences of AD
symptoms and its impact on HRQoL. The first part of the study included three stages: in-person concept elicitation
(CE) interviews, a 2-week daily electronic diary (eDiary) study, and in-person cognitive debriefing (CD) interviews. An
Itch numeric rating scale (NRS) (v1.0) and a Skin Pain NRS (v1.0) evaluation during CD interviews required
participants to think about their ‘worst’ itch and ‘worst’ skin pain in the past 24 h. Other PRO measures allowed for
psychometric testing. The second part of the study involved telephone-depth interviews (TDIs) and qualitative
feedback from participants who had not participated in the CD interviews. Qualitative data were thematically
analyzed. Psychometric evaluation of NRS measures was performed using eDiary data.
Results: In the CE interviews, itch and/or itching and skin pain were the most prevalent symptoms consistently
discussed by participants. Both NRS measures demonstrated strong psychometric reliability and were applicable
across ages with suitable concurrent validity. During the CD interviews, some participants focused their answers on
their ‘average’ itch/itching in the past 24 h, rather than their ‘worst’ itch. Some participants answered the Skin Pain
NRS thinking about general pain or other types of pain, rather than skin pain specifically. Consequently,
modifications to both measures addressed these issues and re-tested as paper-and-pen versions in subsequent
TDIs. Itch NRS (v2.0) modifications helped participants focus on their worst itching. Most participants preferred Skin
Pain NRS v2.0b, which included skin pain descriptors.
Conclusions: Itching and skin pain are the most important and relevant AD symptoms. The Itch NRS (v2.0) and
Skin Pain NRS (v2.0b) appear to be appropriate endpoints for the assessment of itching and skin pain severity for
clinical trials with adults and adolescents with AD.
Keywords: Atopic dermatitis, Itch NRS, Skin pain NRS, Itch, Skin pain, Adolescents, Adults, Health-related quality of
life, Patient-reported outcomes, Clinical outcomes assessment
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Background
Atopic dermatitis (AD) is one of the most common,
chronic, inflammatory skin diseases [1], with a prevalence
of 2% to 10% among adults and 15% to 30% among chil-
dren in Western geographies [2]. The disease is character-
ized by widespread skin lesions which can be red, itchy,
swollen, cracked, and/or weeping/oozing [3]. Predominant
symptoms reported by patients include itch and skin pain
[4]. Patients with moderate to severe AD experience a
heavy disease burden including physical and psychosocial
abnormalities, and a decrease in health-related quality of
life (HRQoL), especially in children [5].
The most common measures used to assess AD sever-
ity include the Investigator Global Assessments (IGAs)
[6], the SCORing Atopic Dermatitis (SCORAD) [7], the
Eczema Area and Severity Index (EASI) [8], and the
Patient-Oriented Eczema Measure (POEM) [9]. Trad-
itional measures are primarily based on visual assess-
ment of clinical signs and symptoms by physicians. To
better understand the burden of AD from the patient
perspective, patient-reported outcome (PRO) measures
are recommended as an important additional assessment
tool [10]. A literature review was conducted which indi-
cated limited evidence of pre-existing PRO tools suitable
for use in a clinical trial setting to assess symptoms such
as itch and skin pain severity as the main concepts of
interest. Of the existing itch measures, the Eppendorf
Itch Questionnaire (EIQ), has been reported in three
studies in terms of its use and/or measurement proper-
ties [11–13], however it has not reported as having been
used in the context of a clinical trial. The EIQ is likely
unsuitable for clinical trial purposes because it includes
127 items, representing a considerable burden on trial
participants. A less burdensome measure, which also has
precedence in clinical trial work is the POEM. The
POEM is a 7-item HRQoL measure that has been rec-
ommended by the HarmoniSing Outcome Measures for
Eczema (HOME) group and focuses on the symptoms of
AD. However, the POEM assesses each symptom in
terms of symptom frequency rather than severity and
produces a total score combining the patient’s response
to itch, disturbed sleep and dermatological symptoms
such as bleeding and flaking skin. Assessing symptom
frequency may not reflect the patients’ experience of
symptom severity, and a total score consisting of a
combination of symptoms may obscure meaningful
treatment benefit relating to reduction in specific
symptoms. In relation to the measurement of pain in
AD, the literature shows that a pain visual analogue
scale [14, 15] and the McGill Pain Questionnaire [16],
have both previously been used as outcome measures
of AD. The measures used in these studies were nei-
ther AD specific, nor focused on dermatological-
related pain.
The existing tools for the assessment of AD-related
itch and skin pain in a clinical trial setting are limited in
their ability to accurately assess the impact of new ther-
apies on the patient-reported symptom severity in AD.
Per guidance from the Food and Drug Administration
(FDA) and European Medicines Agency (EMA), the vari-
ability, duration, and frequency of the symptoms mea-
sured should be factors in choice of the recall period,
and shorter recall periods are typically preferable as reli-
ance on a respondent’s memory over a longer period of
time may undermine content validity. Given the high
daily symptom variability present in AD, 24-h recall is
preferred to allow for the reliable assessment of symp-
toms [10]. As such, we sought to develop a simple,
symptom-specific measures as part of a tool to be ad-
ministered in a daily diary. Numeric rating scale mea-
sures for the daily evaluation of symptoms are
commonly used and a low burden way to assess the
change in the patients’ condition that have previously
been used for the daily assessment of symptomology in
clinical trials [17–21].
This study documents the generation of two patient-
reported symptom specific measures of AD severity that
can be used as clinical trial endpoint measures. This
study used a patient-centered, mixed-methods approach
to collect and assess patient-reported disease symptoms
and impact on HRQoL to gain a better understanding of
AD from the patients’ perspective. Specifically, this study
aimed to identify the concepts most relevant to partici-
pants through concept elicitation, validate the psycho-
metric capabilities of the arising measures and confirm
their content through cognitive debriefing with patients.
Methods
Study design and participants
The study was conducted in two components (Fig. 1).
Component one involved three stages: in stage one, 43
English-speaking participants from the United States
(US) participated in in-person concept elicitation (CE)
interviews, including 28 adult participants (≥18 years
old) and 15 adolescent participants (12–17 years old)
with AD. In stage two of component one, an eDiary
study was conducted for 2-weeks involving all 43 partici-
pants who had taken part in the CE interviews, as well
as another 31 US English speaking participants (22
adults and 9 adolescents) who were newly recruited for
this stage. Thus, stage two of component one had a total
of 74 participants. In the final stage of component one
of the studies, 45 participants (30 adults and 15 adoles-
cents) returned for a cognitive debriefing (CD) interview
no more than 2 days after completing stage two. Among
the 45 participants, 24 had also taken part in stage one
(CE interviews). In component two of the study (which
began 16 weeks after component one ended), 20
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telephone interviews were conducted to evaluate revi-
sions made to the Itch Numeric Rating Scale (NRS) and
Skin Pain NRS. Of the 20 participants (13 adults and 7
adolescents), 13 had also participated in stages one and/
or two of component one of the studies.
Study procedures
Patients aged ≥ 12 years old who were diagnosed with
AD for at least 2 years were recruited by a third-party
recruitment agency using physician referral from out-
patient clinical sites at six cities (Baltimore, Chicago, Los
Angeles, St. Louis, New Orleans, and Philadelphia) in
the US. Participants were eligible if they had a history of
inadequate clinical response to at least one of the follow-
ing: 1) hydration plus topical steroids and/or antibiotics
(eg, tetracycline, trimethoprim, sulfamethoxazole, cepha-
losporins) and/or topical immune modulators (eg, tacro-
limus, pimecrolimus), 2) systemic steroids and/or
phototherapy or 3) cyclosporine and/or other immuno-
modulators (eg, methotrexate, mycophenolate mofetil,
azathioprine). Participants were excluded if they had a
history of any other clinically relevant skin conditions or
a significant psychiatric or physical comorbid condition
including abuse of drugs or alcohol in the past 12
months. All participants were able to read, understand
and give informed consent and adolescent participants
provided assent along with permission/consent from
their parent or legal guardian. Additional patient-
reported demographic and clinician-reported health data
were collected for each participant enrolled by the study
recruiter at each site.
The CE interviews were conducted in-person by a
trained interviewer using a semi-structured discussion
guide. The guide was primarily focused around discus-
sion of participants’ symptom experience with AD and
its impact on their HRQoL. The interviewer initially
asked open-ended questions designed to elicit spontan-
eous discussion, which were then followed by in-depth
probing around the concepts of interest. Interviews were
conducted at a convenient location for the participant
and lasted approximately 1 h.
Following the concept elicitation, two 11-point NRS
items were developed, each with a 24-h recall period.
For itch/itching severity the item required participants
to think about their ‘worst itching’ and respond on a
scale anchored between 0 = ‘no itch’ and 10 = ‘worst itch
imaginable’. For skin pain severity, the item required
participants to think about their ‘worst skin pain’ over
the previous 24 h and respond on a scale between
0 = ‘no pain’ to 10 = ‘worst pain imaginable’ [22].
Fig. 1 Study Flow
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For the daily eDiary stage, all participants received
training on how to use the daily eDiary. The daily eDiary
was programmed to be answered every morning be-
tween 5:00 am and 12:00 pm for 14 days. As well as the
Itch NRS and Skin Pain NRS, the daily eDiary also con-
tained an adapted version of the POEM which was ad-
ministered daily and had a 24-h recall period along with
two global items: a patient global impression of severity
(PGIS) and a patient global impression of change (PGIC)
. The 7-day recall questionnaires were programmed for
completion on Days 0, 7, and 14 of the 2-week period.
Participants were sent an email reminder at the start of
each day’s completion window. The daily eDiary was
programmed so that all questions had to be answered;
participants could not submit partial daily eDiary data.
After the 2-week daily eDiary stage, CD interviews
were conducted to explore the relevance, appropriate-
ness, and interpretability of the daily eDiary. Per the CE
interviews, the CD interviews were conducted in-person
by a trained interviewer using a semi-structured discus-
sion guide and lasted approximately 1 h. The CD inter-
views involved a “think aloud” exercise whereby
participants first verbalized their thoughts while com-
pleting the Itch NRS and Skin Pain NRS in order to ex-
plore their understanding of the items’ instructions,
content, recall period and response scale as well as the
relevance of the concepts measured. To explore inter-
pretation of score change, participants described what
itch and skin pain was like at different points along the
response scale of the NRS measures and where on the
scale they would be to consider a change in the severity
of their itch/itching and skin pain to be meaningful.
For the subsequent telephone CD interviews, the Itch
NRS was reworded to “worst itch” to help participants
focus on their worst itching experience over the previous
24-h. The Skin Pain NRS was also reworded to “worst
skin pain” to help patients focus on their worst skin pain
experience over the previous 24 h. In addition, a second
version of the Skin Pain NRS was developed that in-
cluded descriptors of skin pain in the item anchors to
help define the target symptom. Per the in-person CD
interviews, the telephone CD interviews focused on the
relevance, appropriateness, and interpretability of ver-
sion 2.0 of the NRS measures and, in addition, partici-
pants were asked to select which of the two alternative
versions of the Skin Pain NRS (version 2.0a without de-
scriptors or version 2.0b with descriptors) they preferred
and why.
Ethics
All study documents were submitted and approved by
the US Copernicus Group Independent Review Board®.
The study was performed in accordance with the Declar-
ation of Helsinki and US 21 Code of Federal Regulations
[23]. Participants and their referring clinicians received
remuneration for their participation.
Analytic methods
Demographic and health information data were summa-
rized descriptively using data collected at Day 0 for all
74 participants.
Qualitative analyses of CE data were performed using
ATLAS.ti (v8) software. Data were coded using a mixed
deductive-inductive approach using a pre-specified code-
book along with the creation of new codes derived from
the data as needed. While describing their experiences
of AD, participants were first asked an open-ended gen-
eral interview question about their experiences, concepts
reported in response to this question were coded as
spontaneous. The interviewer then asked probing ques-
tions around the concepts of interest, responses to this
question were coded as probed. The qualitative analyses
of CD data from both the in-person and telephone inter-
views focused adults’ and adolescents’ understanding
and relevance of the target concepts, response scale and
options, and recall periods used in the proposed NRS
measures.
Measurement properties of the NRS measures were
then evaluated using data collected from the eDiary
study. This included examination of response distribu-
tions (based on eDiary data from Days 1, 7, and 14),
test-retest reliability (using intra-class correlation coeffi-
cients (ICCs) calculated between Day 7 and Day 14 and
between Week 1 and 2 average), concurrent validity
(using correlations with the Dermatology Life Quality
Index [DLQI], Children’s Dermatology Life Quality
Index [CDLQI], Skin Pain NRS, Itch NRS and the PGIS
using eDiary data from Days 1, 7, and 14 and the Week
1 and 2 averages (with the exception of the PGIS, no
weekly average generated), and responsiveness (based on
change categories endorsed on the PGIC scores calcu-
lated between Day 7 and Day 14 and between the Week
1 and 2 averages). In terms of guidelines for interpret-
ation, for concurrent validity, the relationship was con-
sidered low if the resulting coefficient was < 0.4,
moderate if 0.4 – 0.7, and large if > 0.7 [24–26]. For test-
retest reliability, ICCs ≥ 0.7 were considered acceptable,
≥ 0.80 were considered acceptable for making judge-
ments on a group basis and ≥ 0.90 for making judge-
ments on an individual participant basis [25]. For
responsiveness, significant differences between patients
who reported a decline on the PGIC and those who re-
ported stability were supported by effect sizes based on
Cohen’s recommendations, the values representing the
magnitudes of responsiveness used in this study were
considered small if the effect size (ES) = 0.20, moderate
if ES = 0.50, and large if ES = 0.80 [26].
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Results
Study population
The total study population (N = 74) was between 12 and
76 years old with a mean time since AD diagnosis of
11.3 years. The study population included 51.4% female
participants and most (41.1%) had moderate AD based
on clinician-reported severity (self-reported AD severity
was consistent with clinician ratings). Caucasian partici-
pants made up 50% of the total study population,
followed by African American participants (32.4%).
Common comorbidities including asthma, food allergy,
and allergic rhinitis were present in approximately 25%
of the study population. Conditions such as attention
deficit hyperactivity disorder, anxiety, and obesity were
present in only a few participants. Table 1 provides a
summary of the key characteristics of the study popula-
tion and by age group.
Component one: findings from the CE interviews (stage 1)
In the CE interviews, participants (n = 43) described ex-
periencing a range of signs and symptoms associated
with their AD; the two most frequently reported were
skin pain (n = 36) and itch (n = 35) (Table 2). When
participants were asked to name their worst symptom,
itch/itching was identified most often by participants
(n = 17). Itch was described as occurring suddenly and
was mainly experienced around the areas of the upper
body, including the arms or elbows (n = 8), neck (n = 6)
and chest (n = 4). Some locations of itch were more
prominent among adults compared with adolescents; for
example, adolescents reported itch/itching more fre-
quently in the knee/leg area [33.3% versus 3.6%] and
adults reported itch/itching more frequently in the arm/
elbow area [21.4% versus 13.3%] and the neck area
[17.9% versus 6.7%]. However, all locations were noted
at least once in both groups. Some participants de-
scribed the severity of itch/itching as dependent on its
duration while others described severity as the intensity
of itch. Seasonality and climate were mentioned as trig-
gers for their itch/itching (n = 19, while others described
using lotions and creams (n = 16), or cold presses and
ice packs (n = 7) to help relieve their itch. Itch was re-
ported as impacting participants’ lives in multiple ways;
n = 12 talked about feeling embarrassed because of
scratching when itching occurs, and n = 10 described
how their itch/itching impacts their social life, primarily
because of scratching in front of others. Seven partici-
pants also reported feeling annoyed, frustrated, and sad
due to the frequency with which they experience itch.
Skin pain was characterized as a burning sensation
(n = 24), soreness or discomfort (n = 24), a stinging sen-
sation (n = 17), a sensitivity (n = 16) and a stabbing feel-
ing (n = 8). Some skin pain descriptions were more
prominent among adults compared with adolescents; for
example, more adults reported burning pain (64% versus
40%), soreness (71% versus 27%), sensitivity (50% versus
13%) and stabbing pain (21% versus 0%), while more ad-
olescents reported stinging pain (67% versus 25%). Par-
ticipants described their skin pain in terms of their
perceptions of severity, which ranged from very minor
to very painful/ very severe. Some skin pain descriptors
were used to refer to milder sensations; for example, one
adult participant rated skin soreness as a 1–4 on a 10-
point scale, whereas skin pain she rated as a 5–10. Like
itch, the triggers for skin pain included the climate and
seasons, contact with the skin, as well as perfumes,
scented lotions, and sweat. Applying cold water or a cold
towel (n = 8) and using creams or lotions (n = 7) were
mentioned by participants as means of coping with skin
pain, however several described the impact it has on
their lives including limitations doing physical activities
(n = 8), at work or school (n = 7), and in their social lives
(n = 6).
Component one: findings from the diary study (stage 2)
The Itch NRS response distribution was examined for
floor and ceiling effects on Days 1, 7, and 14 (Fig. 2).
Overall, the responses were well distributed, with partici-
pants using the majority of the response options at all
time points. Floor and ceiling responses were low and
ranged from 4.8% to 7.3% and 0% to 3.6%, respectively
of the total population. Similar response distributions
were observed in the adolescent and adult subgroups.
Evaluation of test-retest reliability showed that the Itch
NRS was consistent over time (Table 3). For participants
who demonstrated no change on the PGIS (n = 21), the
ICCs between the Day 7 and Day 14 (0.94) and between
the Week 1 to Week 2 average values (0.97) were above
the ≥0.90 ICC threshold [25]. Psychometric analysis also
revealed that the Itch NRS scores showed high correla-
tions with the POEM for both the Week 1 (r = 0.80) and
Week 2 (r = 0.84) average score and moderate to high
correlations on Day 1 with the CDLQI summary score
(0.76) and the DLQI summary score (0.59) (Table 3). In
addition, the Itch NRS had moderate (0.40 ≤ r ≤ 0.70) to
high correlations (≥ 0.70) with the PGIS at Week 1 (r =
0.72) and Week 2 (r = 0.74) and on Day 7 (r = 0.66) and
on Day 14 (r = 0.73). The correlations within the adoles-
cent and adult subgroups fluctuated across time points,
but generally yielded similar values to the total study
population. Overall, participants who reported a decline
on the PGIC (n = 5) showed a statistically significant
greater worsening from the Week 1 to Week 2 average
Itch NRS scores than those who did not report a decline
(n = 24) (mean change of 0.7 versus − 0.4, p = 0.020)
(Table 3). Participants who showed a decline had a large
effect size change (1.21) compared to those who did not
show a decline (0.40).
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Analysis of the response distribution on Days 1, 7, and
14 for the Skin Pain NRS revealed that the most severe
response option did not receive endorsement from any
participant at any time point (Fig. 3). Although an
increase in participants reporting “0” was observed by
Day 14, the variability around these numbers due to the
low participant counts suggests that this was general
variability rather than an improvement over time. Floor
Table 1 Demographic and Clinical Data for the N = 74 Total Study Population
Adolescents (n = 24) Adults (n = 50) Total (N = 74)
Age (years)
Mean (SD) 13.8 (1.94) 48.4 (16.57) 37.2 (21.27)
Median (Min-Max) 13 (12–17) 50 (19–76) 38 (12–76)
Years since diagnosis
Mean (SD) 6.9 (4.34) 13.3 (17.40) 11.3 (14.86)
Median (min-max) 5 (2–17) 7 (0–47) 6 (0–47)
Clinical severity, n (%)a
Mild 8 (33.3%) 11 (22.4%) 19 (26.0%)
Moderate 10 (41.7%) 20 (40.8%) 30 (41.1%)
Severe 6 (25.0%) 18 (36.7%) 24 (32.9%)
Gender, n (%)
Female 11 (45.8%) 27 (54.0%) 38 (51.4%)
Male 13 (54.2%) 23 (46.0%) 36 (48.6%)
Race, n (%)
White/Caucasian 10 (41.7%) 27 (54.0%) 37 (50.0%)
Black/African American 9 (37.5%) 15 (30.0%) 24 (32.4%)
American Indian/Alaska Native 0 (0.0%) 2 (4.0%) 2 (2.7%)
Other/Unknown 5 (20.8%) 6 (12.0%) 11 (14.9%)
Ethnicity, n (%)
Not Hispanic/Latino 22 (91.7%) 46 (92.0%) 68 (91.9%)
Hispanic/Latino 2 (8.3%) 3 (6.0%) 5 (6.8%)
Unknown 0 (0.0%) 1 (2.0%) 1 (1.4%)
Prior treatment, n (%)
Yes 23 (95.8%) 43 (86.0%) 66 (89.2%)
No 1 (4.2%) 7 (14.0%) 8 (10.8%)
Comorbidities
Allergic rhinitis, n (%) 9 (37.5%) 13 (26.0%) 22 (29.7%)
Asthma, n (%) 8 (33.3%) 11 (22.0%) 19 (25.7%)
Food allergy, n (%) 4 (16.7%) 12 (24.0%) 16 (21.6%)
Anxiety, n (%) 0 (0.0%) 3 (6.0%) 3 (4.1%)
Obesity, n (%) 0 (0.0%) 3 (6.0%) 3 (4.1%)
ADHD, n (%) 1 (4.2%) 1 (2.0%) 2 (2.7%)
Patient assessed symptom severity, n (%)
Not Severe at All 0 (0.0%) 2 (4.0%) 2 (2.7%)
Very Mild 1 (4.2%) 7 (14.0%) 8 (10.8%)
Mild 13 (54.2%) 7 (14.0%) 20 (27.0%)
Moderate 7 (29.2%) 17 (34.0%) 24 (32.4%)
Severe 2 (8.3%) 16 (32.0%) 18 (24.3%)
Very Severe 1 (4.2%) 1 (2.0%) 2 (2.7%)
aAs assessed by a 5-point Investigator Global Assessment
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responses ranged from 21.0% (on Day 1) to 40.5% (on
Day 14) of the total study population. The Skin Pain
NRS showed good test-retest reliability with participants
who reported no change on the PGIS (n = 21) showing
consistent scores over time. ICCs between Day 7 and
Day 14 (0.91) and between the Week 1 and Week 2
average values (0.97) were above the ≥0.90 ICC thresh-
old. Concurrent validity was also strong with high corre-
lations between the Skin Pain NRS weekly average
scores and POEM scores at Week 1 (r = 0.75) and Week
2 (r = 0.77) and on Day 1 with the CDLQI summary
score (r = 0.90) and the DLQI summary score (r = 0.57).
In addition, the Skin Pain NRS had moderate correla-
tions with the PGIS for both Week 1 (0.68) and Week 2
(0.65) average score and on Day 7 (r = 0.63) and on Day
Table 2 Signs and Symptoms Identified by N = 43 Participants in the CE Interviews
Sign/
Symptom
Identified
Example Participant Quote Adolescents
(n = 15)
Adults
(n =
28)
Total
(N =
43)
S P S P
Skin pain “I mean, it can be quite severe, actually. I have a pretty high pain threshold … but I’ve had it hurt. I’ve
had outbreaks where it was raw and weepy and it hurt enough that I would really cry.” (Male adult)
2 13 3 18 36
Itch “I have these two spots. One’s on my upper thigh, and one’s on my lower calf. One’s on the right
side, one’s on the left side. And they just pop up randomly. They will itch … I think I am going to
lose my mind. It’s a bad, bad itch.” (Female adult)
4 8 8 15 35
Redness “The redness because it makes me look like a baboon’s butt … because it’s super red.” (Male
adolescent)
2 13 5 15 35
Scratch/
Scratchy
“It just feels kind of just- very just scratchy.” (Female adolescent) 3 5 8 8 24
Dry skin “If I was petting … like uh, one of the lizards … rough and … dry.” (Male adolescent) 2 9 8 3 22
Bleeding skin “It’ll sometimes bleed when I am asleep and then I’ll have blood on my bed and my arm.” Male
adolescent)
1 5 3 6 15
Bumps “They’re like little bumps with like white tips on them. They feel like your … if you have a lot in a
place it’ll feel like bumpy.” (Female adolescent)
1 8 1 4 14
Cracking skin “It almost, like, cracks. I feel like shoe leather, sometimes … you know, real dry and brittle.” (Male
adult)
1 4 2 4 11
Rash “It’s like a rash. Like if you used to have a rash you used to scratch it and be like red-ish and stuff. Just
like a whole bunch of bumps in one area.” (Female adolescent)
1 2 4 1 8
Burns “Then you start to itch, and you feel it … there’s like a little burning feel, like someone’s lighting a
match under you … or a lighter.” (Male adult)
1 2 1 2 6
Scaling “Scaliness is like a snake or something like that … but this is just how the bumps on your skin feel.
Like normal. A person who don’t have the condition wouldn’t say a whole bunch of bumps on they
skin. They’d say ‘oh you feel like … you feel scaly.’” (Female adolescent)
1 1 2 0 4
Peeling/
flaking skin
“It was just a constant … scratching and flaking and drying skin. It’s improved considerably over the
years, but I’ll still get patches where skin will get a dry patch here and a crack.” (Male adult)
0 5 0 2 7
Skin
discoloration
“I have it right here on my arm. And they all … usually look like bruises.” (Female adult) 1 0 1 3 5
Inflammation “Actually, it stays hot the whole time until it is healed. Remember inflammation, part of inflammation
is heat.” (Female adult)
0 1 0 4 5
Tightness “It is almost like a tightness. Like the skin is being pulled tauter.” (Female adult) 0 2 0 2 4
Discomfort “I don’t know whether the word pain or just discomfort. I think discomfort probably … it’s better than
pain because I can’t truthfully say that I’ve been in pain before.” (Male adult)
0 0 0 3 3
Irritation “Irritation is like when you’re starting a toothache. It’s a little painful when it’s starting. So, if you don’t
take care of it, it continues … until it’s time to go to the dentist.” (Female adult)
0 0 0 2 2
Abbreviations: P Probing, S Spontaneously
Fig. 2 Item Distribution for the Itch NRS and Floor-Ceiling Effects of
the Response Levels
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14 (r = 0.68). The correlations within the adolescent and
adult subgroups fluctuated across time points, but gen-
erally yielded similar values to the total study popula-
tion. Analysis of responsiveness revealed that
participants who reported a decline on the PGIC (n = 5)
showed statistically significant greater worsening from
the Week 1 to Week 2 average Skin Pain NRS scores
than those who did not report a decline (n = 39) (mean
change of 0.9 versus − 0.3, p = 0.003). This is supported
by a large effect size of 1.09 in the decline group
compared to a small effect size of 0.34 in the group who
did not report decline.
Component one: findings from the CD interviews (stage 3)
Forty-five CD interviews were conducted and analyzed
to explore participants’ understanding of item content,
the relevance of the concept measured, and the appro-
priateness of the response scale and options as well as
the recall period. Overall, there were no differences be-
tween adolescent and adult participants in their under-
standing of the content, relevance, response scale and
options, or recall period for the two NRS measures.
A total of 44 participants demonstrated a good under-
standing of the concept of itch/itching as described in
the wording of the Itch NRS. There was clear alignment
between the item wording and the language used by par-
ticipants in the CE interviews to talk about their itch ex-
periences, for example, one adolescent described his
experience: “How do you rate the severity the itch caused
by your skin condition over the past seven days? I would
um, rate this a little bit higher, it’s moderate, because
when my skin got dry because I took a warm bath or I
didn’t put on the medicine, then it started getting, then it
started itching a little bit, and the longer I didn’t put on
the medicine it would start itching more”. Another
Table 3 Results of Psychometric Analysis of Real-World Daily eDiary Data
Parameter Itch NRS[a] Skin Pain NRS[a]
Test-retest reliability[b] (n = 31)
Week 1 to Week 2 Average 0.95 0.97
Day 7 to Day 14 0.94 0.91
Concurrent validity[c]
POEM (Week 1; n = 74) 0.80 0.75
POEM (Week 2; n = 66) 0.84 0.77
PGIS (Week 1; n = 55) 0.72 0.68
PGIS (Week 2; n = 42) 0.74 0.65
DLQI Summary Score (Adult population; n = 33–53) 0.59–0.74 0.57–0.73
CDLQI Summary Score (Adolescent population; n = 9–19) 0.76–0.89 0.77–0.91
Responsiveness[d]
Week 1 to Week 2 Average p = 0.02 p = 0.003
Decline ES = 1.21 (n = 5) ES = 1.09 (n = 5)
No Decline ES = 0.41 (n = 24) ES = 0.34 (n = 39)
Day 7 to Day 14 p = 0.25 p = 0.42
Decline ES = 0.40 (n = 5) ES = 0.24 (n = 5)
No Decline ES = 0.08 (n = 24) ES = 0.04 (n = 24)
Abbreviations: CDLQI Children’s Dermatology Life Quality Index, DLQI Dermatology Life Quality Index, NRS Numeric rating scale, PGIS Patient Global Impression of
Severity, POEM Patient Oriented Eczema Measure, ES Effect size
[a]The NRS scales ranged from 0 to 10
[b]Test-retest calculation assessed score changes from Day 7 and Day 14 and the Week 1 to Week 2 average in patients who showed a 0- or 1-point change on
the PGIS scale
[c]Correlations performed on Day 1, 7, 14, and the Week 1 to Week 2 average except for PGIS, which was only collected at Day 7 and 14
[d]p-value from test for difference in mean score change of participants who scored above and below 4 on the PGIC between Weeks 1 and 2 and Day 7 and
Day 14
Fig. 3 Item Distribution for the Skin Pain NRS and Floor-Ceiling
Effects of the Response Levels
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adolescent appeared to correctly think about itch/itching
as distinct from other symptoms when describing his
chosen response to the Itch NRS, however he conflated
itch and skin pain when asked to interpret the item
using his own words: “Uh, like how much pain, like how
much pain did you have from [inaudible], like zero
means, like, none, and 10 means, like, the most you’ve
ever felt”. In addition, participants in the in-person CD
interviews commented that the measurement concept of
itch/itching was highly relevant based on their own dis-
ease experiences, for example, an adult described his ex-
perience: “I itched the day before, and I itched the day
before that, and … I’ve been itching the last 20 years”.
Five participants reported that they experience itch but
responded ‘0’ to this item because they had avoided trig-
gers. The 0 to 10 response scale was adequate and well
understood, for example participants who scored ‘0’ ex-
perienced no itch in the past 24 h: “I didn’t have any itch
in the past 24 hours. So, that’s why I selected no itch.” In-
deed, most participants reported thinking back over 24 h
when answering the question, supporting the appropri-
ateness of the recall period. When asked, 25 participants
appeared to answer the Itch NRS thinking about their
itch in general over the past 24 h or how bad their itch/
itching was on average compared to their worst itch/
itching ever: “Interviewer: Okay. And so, when I say,
‘worst itching,’ what do you think we mean? Participant:
Like, how bad … the intensity.” Indeed, two participants
suggested that the Itch NRS could be improved by pro-
viding more explanation of what is meant by ‘worst’ itch:
“a little more details to what’s included in your worst
itching, what makes it worse? I was just guessing as far
as choosing a number. A six is not as high of a number
but higher than average.”
The Skin Pain NRS was also well-understood by the
majority of participants in the in-person CD interviews,
noting it as a relevant symptom. Based on qualitative
feedback, the response scale and recall period appeared
to be suitable for these participants: “Uh, I’m gonna say
a four because it did sting a little last night. Like it did
hurt, but it wasn’t too bad. It wasn’t, like, enough, like to
make me cry or anything.” However, there were some
participants whose interpretation of the question was
not as intended; for example, three participants reported
thinking about skin pain and itch/itching when answer-
ing the NRS, two participants reported thinking about
all types of pain (ie, not specifically skin pain), one par-
ticipant was unclear about the type of pain being re-
ferred to and finally, one participant reported that he
excluded skin pain caused by scratching due to itch. In-
deed, four participants suggested describing the type of
skin pain in the item wording to clarify its meaning. In
addition, three participants reported that they had never
experienced skin pain due to AD, and one participant
felt that other pain descriptors should be used to capture
less severe sensations: “Maybe they could even say, um,
irritation, or, like, agitated skin, maybe… It’s just hard to
imagine your skin being painful. Like, I just wouldn’t de-
scribe it as painful. This [item] is like, I’m a burn victim
or something”. In terms of the level of change partici-
pants considered meaningful using the Skin Pain NRS,
there was no clear preference, but a 1- or 2-point change
appeared beneficial to the majority of participants.
The findings from Stage 2 indicated that the Itch NRS
and Skin Pain NRS were psychometrically valid mea-
sures of the target concepts and were responsive to
changes in condition across the age categories. Both the
Itch NRS and the Skin Pain NRS demonstrated reliabil-
ity over time and exhibited concurrent validity (ie, mod-
erate - high correlations (0.65–0.84) with concurrent
measures). Despite these results, the in-person CD inter-
views conducted in Stage 3 revealed some specific meas-
urement issues based on participants’ feedback. For the
Itch NRS, it was not clear if participants were correctly
rating their worst itch/itching or averaging across all
itch/itching episodes within the 24-h period. In addition,
for the Skin Pain NRS, a few participants felt the term
“pain” may be too severe or were unclear if milder sen-
sations should be considered when answering this ques-
tion. Therefore, we made modifications to address these
concerns and subsequently tested the revised versions of
the NRS measures in telephone CD interviews. The
wording of the Itch NRS was revised to help participants
appropriately interpret the concept of ‘worst’ itch, ie,
“worst level of itching”. To maintain consistency be-
tween the two measures, the wording of the Skin Pain
NRS was modified in line with these revisions. An alter-
native version of the Skin Pain NRS was also created
with descriptors of skin pain in the item stem with a
view to capture pain experiences that participants may
consider “less severe” and help participants to focus on
skin pain specifically, rather than general pain or other
types of pain. The recall period and response scale and
options were retained per the original versions of the
measures.
Component two: findings from the telephone CD
interviews
In the telephone CD interviews, all 20 participants de-
scribed their chosen responses to the revised Itch NRS
in terms of itch/itching severity or in terms of the inten-
sity of their need to scratch. Of the 13 participants who
were asked about their interpretation of the concept of
‘worst itch’ based on how it was described in the item
wording, five reported that they answered in terms of
how bad their itch/itching had been at its worst point in
the day. Eight participants commented that they an-
swered thinking about the severity of their itch/itching
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over the whole 24-h period and compared this to their
worst itch ever. Consistent with the in-person CD inter-
views, there were no issues raised in terms of the re-
sponse scale or recall period. Similarly, when asked what
score change would be meaningful using the revised Itch
NRS, participants asked stated that a 3- to 4-point (n =
8; 40%) reduction would be ideal, again consistent with
the in-person CD findings. Regarding the two revised
versions of the Skin Pain NRS, both were well-
understood, yet more participants (n = 19 vs. n = 14) ap-
peared to understand the target concept when it was
presented alongside the skin pain descriptors (v2.0b)
compared to the version without the descriptors (v2.0a).
For example, two participants were unsure if v2.0a was
exclusive to itching/scratching or if it related to skin
pain caused by other factors, and four participants inter-
preted the question as asking about pain and itch. In
contrast, just one participant mentioned that he thought
about itching as well as skin pain when answering v2.0b
of the NRS. Participants also gave feedback on the de-
scriptors used in v2.0b. No issues were reported and
when asked which other terms could be used to describe
skin pain, n = 11 participants suggested adding ‘burning/
hot’, n = 7 suggested ‘ache’ and n = 3 suggested ‘stinging’.
These terms were similar to those spontaneously used
by participants in the CE interviews to describe their
skin pain experiences. When asked what score change
would be meaningful on each of the two revised versions
of the Skin Pain NRS, there was no clear pattern or dis-
cernable best score change among participants.
Discussion
The objective of this research was to incorporate the pa-
tient voice in the development of valid and reliable pa-
tient outcomes in AD. This study incorporated mixed
research methods to ensure that the measurement prop-
erties of the two generated measures captured daily
symptoms. The first stage of this study was undertaken
to gather insights from adults and adolescents regarding
the symptoms and impacts of AD from the patient per-
spective. All participants in the CE interviews commen-
ted that itch/itching and skin pain are the worst
symptoms associated with AD and described them as
priority areas for treatment. Adults and adolescents with
AD described very similar disease experiences that nega-
tively affected their quality of life including their ability
to do physical tasks, as well as feeling embarrassed or
ashamed in front of others. Thus, there was clear overlap
between adults’ and adolescents’ AD symptoms and
HRQoL experiences, indicating that a consistent meas-
urement approach can be implemented across these age
ranges.
Indeed, to capture the severity of itch/itching and skin
pain from the perspective of adult and adolescent AD
patients, two patient-reported NRS measures were de-
veloped and tested in the subsequent stages of this
study. In component one, the Itch NRS performed well
both qualitatively and quantitatively and was shown to
be a valid, reliable, and sensitive measure of AD-related
itch. However, revisions were made in response to the
finding that not all participants thought about their
worst itch/itching when answering the question. Findings
from the telephone CD interviews (component two)
demonstrated that the revisions to the Itch NRS im-
proved participants’ understanding of the target concept
consistent with the intended meaning. Similarly, the Skin
Pain NRS was shown to be both valid and reliable based
on the in-person CD interviews and daily eDiary study,
but revisions were also made to maintain consistency
with the updated format of the Itch NRS as well as to
test the utility of including skin pain descriptors within
the item stem itself. Findings from the telephone CD in-
terviews (component two) revealed that both revised
versions of the Skin Pain NRS were fit for purpose.
However, participants preferred the version with the de-
scriptors as it was better understood and better repre-
sented their overall skin pain experiences.
Findings from the quantitative analysis support that
original versions of both the Itch NRS and Skin Pain
NRS are reliable at both the group and individual patient
level [25]. The modifications to the tools were made to
improve comprehension rather than to address psycho-
metric weaknesses. Since the modifications were shown
to address the comprehension issue, quantitative evi-
dence supporting the original versions will likely hold
true, or perhaps be enhanced, for the revised measures.
Nonetheless, future research using this revised tool
should aim to confirm the psychometric properties of
these measures. Specifically, the magnitude of change,
denoted by the ES parameter, should be replicated in a
larger clinical population. Effect size (ie, ES) is a random
variable and sensitive to sample variability which is re-
lated inversely to sample size [27, 28]. In this mixed
methods study, the observed larger effect size (ES = 0.40)
in the stable population can be attributed to the variabil-
ity in this small sample population.
In the telephone CD interviews, both measures were
well understood, but it was noted that over half of par-
ticipants in component two of the study suggested add-
ing “burning” to the list of descriptors within the Skin
Pain NRS (v2.0b). In the CE interviews, a burning sensa-
tion was described by some participants as a painful ex-
perience but for others, the term was used to describe
the redness of their skin or the feeling of heat on their
skin that was not seen as a ‘painful’ sensation. Given the
different ways the term ‘burning’ was used by partici-
pants in the CE interviews, it was agreed that it should
not be included as a descriptor of skin pain since those
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who did not consider it a painful experience would likely
find this confusing. Furthermore, the overwhelming ma-
jority of participants in the telephone CD interviews
understood the concept as it was described in v2.0b of
the Skin Pain NRS and felt that the existing descriptors
were sufficient in helping them to understand the
intended meaning of the concept.
Thresholds for interpreting change on both measures
were qualitatively explored; in the CD interviews, both
in-person and telephone, participants indicated a mean-
ingful change threshold between 3 and 4 points for the
Itch NRS. For the Skin Pain NRS, there was no clear pat-
tern based on qualitative feedback, which may be in part
due to participants generally scoring at the low end of
the response scale for the Skin Pain NRS. Therefore, fur-
ther evidence is required to determine the most appro-
priate responder thresholds for both measures; this is
currently being explored as part of a longitudinal, inter-
ventional, study with adult AD patients in which full
psychometric validation of the revised measures is also
being undertaken.
Conclusions
This study has addressed the previously identified gap in
AD PRO measurement literature by creating two mea-
sures that assess symptoms of itching and skin pain. Re-
visions made to improve the validity of the measures
were drawn directly from the recommendations of pa-
tients with AD who completed and provided feedback
on initial versions of the measures and through supple-
mentary interviews with additional AD patients follow-
ing revisions to the measure. Participants reported day-
to-day variations in AD symptomology, and therefore
the measures were revised to a daily, 24-h recall period
to better capture experience with these symptoms. Exist-
ing measures in the field rely on a retrospective 7-day
recall period [15, 28], this study suggests that is not ad-
equate for capturing the day-to-day variation experi-
enced by patients with AD and may impact validity of
the measure. Further, following the revisions to the mea-
sures, this study utilized qualitative and quantitative data
from patients with AD show that the new measures are
both valid and reliable and adequate for use.
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